BioSig Technologies, Inc. (BSGM) News
Filter BSGM News Items
BSGM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BSGM News From Around the Web
Below are the latest news stories about BIOSIG TECHNOLOGIES INC that investors may wish to consider to help them evaluate BSGM as an investment opportunity.
BioSig Regains Compliance with Nasdaq’s Minimum Bid Price RequirementLos Angeles, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced that it has received notice from the Nasdaq Listing Qualifications staff ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). To regain compliance wi |
BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ PanelLos Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or the “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company’s common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March |
BioSig intends to acquire Neuro-Kinesis’ assetsThe transaction will involve payment through the issuance of BioSig’s common stock to NKC shareholders. |
BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis CorporationLos Angeles, July 31, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization for electrophysiology (EP) procedures, today announced the intent to acquire the assets of Neuro-Kinesis Corporation (NKC), a privately held Los Angeles-based medical technology company developing smart EP tools. A non-binding letter of intent (LOI) has been executed confi |
BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that it has successfully negotiated with multiple vendors an initial reduction in accounts payable of approximately $1.5 million during the second quarter of 2024 since new management has taken leadership. One substantial savings recogn |
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting OfficerWestport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer. Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He c |
BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWestport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share and concurrent private placement unreg |
BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWestport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share in a registered direct offering priced at-the-market under Nasdaq rules. |
BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to ShareholdersWestport, CT, May 21, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, has today issued the following Letter to Shareholders: Dear Shareholders, As the new CEO of BioSig, I am committed to keeping our shareholders updated to the best of my ability on the progress of our Company. Our new management team is firmly committed to both restoring |
BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 IndependentWestport, CT, May 03, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced new appointments to its now fully constituted board of directors (the “Board”), which is comprised of a total of five (5) directors, three (3) of whom are classified as independent directors. The final compositions of the committees to the Board wi |